Kazano

Physical Activity, Type 2 Diabetes, Diet
Treatment
4 FDA approvals
20 Active Studies for Kazano

What is Kazano

AlogliptinThe Generic name of this drug
Treatment SummaryAlogliptin is an oral medication used to block the activity of an enzyme called dipeptidyl peptidase-4 (DPP-4). It is available as a salt and is mostly made up of the R-enantiomer form. Alogliptin was approved by the FDA in 2013.
Nesinais the brand name
image of different drug pills on a surface
Kazano Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Nesina
Alogliptin
2013
26

Approved as Treatment by the FDA

Alogliptin, also known as Nesina, is approved by the FDA for 4 uses which include Type 2 Diabetes Mellitus and Physical Activity .
Type 2 Diabetes Mellitus
Used to treat Type 2 Diabetes Mellitus in combination with Pioglitazone
Physical Activity
Used to treat Exercise in combination with Pioglitazone
Type 2 Diabetes
Used to treat Type 2 Diabetes Mellitus in combination with Pioglitazone
Diet
Used to treat Diet in combination with Pioglitazone

Effectiveness

How Kazano Affects PatientsAlogliptin is effective within 2-3 hours of taking a single dose, and can keep working for up to 24 hours if taken in a dose of 25 mg or higher. It reduces the amount of glucagon produced after eating, and increases the amount of active GLP-1 in the body. Alogliptin does not have any effect on the heart's electrical activity.
How Kazano works in the bodyAlogliptin helps control blood sugar levels by blocking an enzyme that breaks down two hormones that regulate blood sugar. These hormones, called incretins, stimulate the pancreas to produce insulin and suppress the production of glucagon. They also make you feel full and reduce the amount of food you eat. Blocking the enzyme that breaks them down allows more of these hormones to remain active, helping to control your blood sugar.

When to interrupt dosage

The prescribed dosage of Kazano is contingent upon the specified condition, including Diet, Physical Activity and Type 2 Diabetes. The magnitude of dosage is based on the technique of administration indicated in the table below.
Condition
Dosage
Administration
Diet
, 6.25 mg, 12.5 mg, 25.0 mg
, Tablet - Oral, Oral, Tablet, Tablet, film coated, Tablet, film coated - Oral
Type 2 Diabetes
, 6.25 mg, 12.5 mg, 25.0 mg
, Tablet - Oral, Oral, Tablet, Tablet, film coated, Tablet, film coated - Oral
Physical Activity
, 6.25 mg, 12.5 mg, 25.0 mg
, Tablet - Oral, Oral, Tablet, Tablet, film coated, Tablet, film coated - Oral

Warnings

There are 20 known major drug interactions with Kazano.
Common Kazano Drug Interactions
Drug Name
Risk Level
Description
Amitriptyline
Major
The metabolism of Amitriptyline can be decreased when combined with Alogliptin.
Amoxapine
Major
The metabolism of Amoxapine can be decreased when combined with Alogliptin.
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Alogliptin.
Clomipramine
Major
The metabolism of Clomipramine can be decreased when combined with Alogliptin.
Clonidine
Major
The metabolism of Clonidine can be decreased when combined with Alogliptin.
Kazano Toxicity & Overdose RiskCommon side effects of alogliptin include a stuffy or runny nose, headaches, and a cold or other upper respiratory infection.
image of a doctor in a lab doing drug, clinical research

Kazano Novel Uses: Which Conditions Have a Clinical Trial Featuring Kazano?

196 active clinical trials are investigating the utility of Kazano in augmenting Physical Activity, ameliorating Type 2 Diabetes and optimizing Diet.
Condition
Clinical Trials
Trial Phases
Diet
5 Actively Recruiting
Not Applicable, Phase 1
Physical Activity
24 Actively Recruiting
Not Applicable, Phase 1, Phase 2
Type 2 Diabetes
167 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

Kazano Reviews: What are patients saying about Kazano?

5Patient Review
4/6/2021
Kazano for Type 2 Diabetes Mellitus
I don't know why, but metformin alone makes my stomach unbearably upset. With Kazano my blood sugar levels are great and I have no GI issues.
3.7Patient Review
9/5/2013
Kazano for Type 2 Diabetes Mellitus
3.7Patient Review
12/19/2013
Kazano for Type 2 Diabetes Mellitus
3.3Patient Review
5/18/2016
Kazano for Type 2 Diabetes Mellitus
For the past two years, this medication has been great for keeping my A1c levels down. However, I've recently noticed that my blood sugar is always high, especially in the morning. Nothing else in my routine has changed, so I think it might be time to switch medications.
3.3Patient Review
2/28/2014
Kazano for Type 2 Diabetes Mellitus
I was really sweating a lot, my eyes were watery, and I had a runny nose.
3Patient Review
9/29/2014
Kazano for Type 2 Diabetes Mellitus
Unfortunately, I experienced some pretty intense diarrhea. This also came with nausea and a loss of appetite.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about kazano

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Kazano?

"An upper respiratory tract infection can cause symptoms like a stuffy nose, sinus pain, and a sore throat. Other possible causes of these symptoms include a cold, a headache, back pain, a urinary tract infection, high blood pressure, and diarrhea."

Answered by AI

What is Kazano used for?

"Kazano is a combination medication containing alogliptin and metformin. This medication is designed to be used in conjunction with diet and exercise to improve blood sugar control in people with type 2 diabetes."

Answered by AI

How much does Kazano cost?

"The price of Kazano oral tablets (12.5 mg-500 mg) varies depending on the pharmacy, but is around $440 for a supply of 60 tablets. This price is for cash paying customers only and does not apply to customers with insurance plans."

Answered by AI

What are Gliflozin drugs?

"This class of drugs is used to lower high blood glucose levels in people with type 2 diabetes by inhibiting the SGLT-2 proteins located in the renal tubules of the kidneys, which are responsible for reabsorbing glucose back into the blood."

Answered by AI

Clinical Trials for Kazano

Image of University of California, Los Angeles in Los Angeles, United States.

Tailored DPP for Prediabetes

17 - 25
All Sexes
Los Angeles, CA
The goal of this study is to enhance reach and uptake of diabetes prevention among young adults, with a focus on recruiting underserved and high-need students who face additional challenges, including food and financial insecurity. The specific aims are: Aim 1 - Evaluate the efficacy of an AYA-tailored version of the UC DPP for mitigating type 2 diabetes risk (i.e., weight change) in a pre/post pilot trial. The investigators hypothesize that the AYA-tailored intervention will be effective at producing 5% weight loss from baseline to program completion (at 9-months). Aim 2 - Assess the feasibility and acceptability of an AYA-tailored version of the UC DPP program. The investigators hypothesize that it will be feasible to recruit the desired number of participants given proposed innovative outreach strategies, and that the AYA-tailored intervention will be deemed acceptable to participants both qualitatively and in regards to their retention in the program at rates similar to the larger UC DPP. The investigators will recruit 80 UCLA undergraduate students. Participants will be asked to complete a brief screening online form to assess eligibility and to collect contact information. The PI and/or Research Assistants (RAs) will reach out to eligible participants to obtain informed consent and enroll them in the pilot trial. The investigators will randomize participants to the tailored DPP cohort vs control cohort. Control participants will be offered the opportunity to participate in the tailored DPP in the following academic year. The tailored DPP intervention will be online and asynchronously. Participants will be asked to complete the intervention lessons on their own time. Each lesson typically takes on average 15 minutes to complete. Control group will receive each intervention materials via e-mail for participants to review on their own time and will receive acceptability surveys. The interventions for the control group will be remote. A research assistant will meet with control participants via Zoom to explain the intervention materials. Control group will receive access to a study habits intervention, alcohol use intervention, and financial literacy intervention. At the end of each quarter (Fall, Winter, and Spring), both control and intervention participants will receive an email with a unique link to a brief REDCap survey to ascertain acceptability of sessions/lessons. Furthermore, participants will complete baseline and 9-month follow-up assessments. Participants will complete a 30 minute questionnaire and height/weight measurements will be collected by a RA. Participants will be asked to self-report weight and physical activity at the end of the fall and winter quarter; data will be collected via brief REDCap survey.
Recruiting
Has No Placebo
University of California, Los AngelesLauren E Wisk, PhD
Image of Medpace Clinical Pharmaology Unit in Cincinnati, United States.

PATAS for Type 2 Diabetes

18 - 55
All Sexes
Cincinnati, OH
The primary objective of Part 1 of this study is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy subjects. The secondary objective of Part 1 of this study is to determine the pharmacokinetics (PK) of single SC doses of PATAS in healthy subjects. The primary objectives of Part 2 of this study are to evaluate the safety and tolerability of 4 weekly SC doses of PATAS in subjects with T2D; and to determine the PK and pharmacodynamics (PD) of 4 weekly SC doses of PATAS in subjects with T2D. The secondary objectives of Part 2 of this study are to evaluate the potential effect of multiple SC doses of PATAS on markers of glycemic control, as measured by glucose levels, insulin levels, and other metabolomic biomarkers; and to characterize the adverse event (AE) profiles of the various dose levels of PATAS.
Phase 1
Waitlist Available
Medpace Clinical Pharmaology UnitVincent Marion, Ph.D.AdipoPharma LLC
Have you considered Kazano clinical trials? We made a collection of clinical trials featuring Kazano, we think they might fit your search criteria.Go to Trials
Image of The Worship Center Cristian Church in Birmingham, United States.

Black Impact for Heart Health

18+
Male
Birmingham, AL
The goal of this clinical trial is to evaluate the implementation and effectiveness of the Black Impact program-a church-based cardiovascular health (CVH) intervention-in Black men aged 35-70 who are at risk for heart disease, diabetes, obesity, and related conditions. The main questions this study aims to answer are: * Does participation in the Black Impact program improve cardiovascular health metrics (e.g., blood pressure, cholesterol, blood sugar) and health behaviors among Black men at The Worship Center Christian Church (TWC)? * What factors influence the adoption, delivery, and sustainability of the Black Impact program in a faith-based setting? Researchers will compare an immediate-start intervention group and a delayed-start (waitlist control) group to assess both short-term health outcomes and program implementation factors. Participants will: * Attend a 90-minute weekly session for 24 weeks, including 45 minutes of physical activity led by a certified trainer and 45 minutes of health education delivered by trained coaches. * Receive one-on-one support from a community health worker to reduce barriers to care and engage with primary care. * Complete biometric health screenings and surveys at baseline, 12 weeks, and 24 weeks to assess clinical and behavioral outcomes. * Use a smartwatch, blood pressure cuff, and other tools to track progress in real time. * Participate in exit focus groups or interviews to share feedback about the intervention. * A subset of TWC leaders and interventionists (N=15) will also be interviewed to assess implementation, resource needs, and sustainability. This study uses the RE-AIM framework to assess Reach, Effectiveness, Adoption, Implementation, and Maintenance, and aims to inform scalable strategies for improving CVH among Black men in trusted community settings.
Waitlist Available
Has No Placebo
The Worship Center Cristian Church
Have you considered Kazano clinical trials? We made a collection of clinical trials featuring Kazano, we think they might fit your search criteria.Go to Trials
Image of Exercise Metabolism and Inflammation Laboratory in Okanagan, Canada.

Aerobic Exercise with Blood Flow Restriction for Type 2 Diabetes

19 - 64
All Sexes
Okanagan, Canada
The goal of this trial is to learn if blood flow restriction training with treadmill walking is possible for individuals living with type 2 diabetes. It will also learn about how the blood flow restriction with treadmill walking could improve health. The main questions it aims to answer are: Is 6 weeks of treadmill walking with blood flow restriction reasonable for people with type 2 diabetes to perform? Does treadmill walking with blood flow restriction training help manage type 2 diabetes better than just treadmill walking? Researchers will compare treadmill walking with blood flow restriction to treadmill walking without blood flow restriction to see if blood flow restriction works to manage type 2 diabetes based on fitness and blood sugar levels. Participants will: Perform treadmill walking with or without blood flow restriction for 96 minutes a week for 6 weeks. Visit the lab before and after the exercise for tests and questionnaires.
Waitlist Available
Has No Placebo
Exercise Metabolism and Inflammation Laboratory (+2 Sites)Martin Senechal, PhD
Image of Jefferson Health New Jersey in Sewell, United States.

Continuous vs Finger-stick Glucose Monitoring for Type 2 Diabetes in Pregnancy

18+
Female
Sewell, NJ
The purpose of this study is to compare patient adherence to blood sugar monitoring during pregnancy using two different measurement methods in pregnancies complicated by pregestational type 2 diabetes (T2DM). Pregnant patients with T2DM are at risk of having larger babies, babies with low sugar levels in the first 24 hours of life, higher rates of cesarean delivery, stillbirth (death of baby inside the womb), and hypertensive or high blood pressure disorders of pregnancy, such as preeclampsia. Prior studies have shown that treating high blood sugars in pregnancy with medications can reduce these risks. To determine the amount of medication needed, recording of blood sugar levels is necessary. This trial aims to determine whether continuous blood sugar monitors have improved patient recording of blood sugar levels over finger stick blood sugar measurements. Patients involved in the study will be assigned to either: 1. Fingerstick glucose monitoring (FSG) 2. Continuous glucose monitoring (CGM) Patients will be randomize in a 1:1 ratio. FSG Group: blood sugar is tested four times daily - once fasting and two hours after every meal (post-prandial). Blood will be tested using a glucometer, and values will be recorded in a blood sugar log from the time of enrollment to the time of delivery. CGM Group: A CGM sensor will be placed on the patient's arm for blood sugar collection every 3-5 minutes. This data is sent to a phone application from the time of enrollment to the time of delivery. These sensors will need to be replaced every 14 days. Percent adherence will be recorded from the time you were randomized to a study group until delivery.
Recruiting
Has No Placebo
Jefferson Health New Jersey (+1 Sites)
Have you considered Kazano clinical trials? We made a collection of clinical trials featuring Kazano, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security